Journal of Clinical Medical Research, Год журнала: 2025, Номер unknown, С. 1 - 28
Опубликована: Янв. 31, 2025
The emergence of new variants concern in immunocompromised persons with SARS-CoV-2, particularly those mutations the spike protein, has complicated treatment strategies. Some Therapies focused only on viral clearance effects and not major clinical outcomes. As virus continues to evolve, development broad-spectrum therapies, along personalized approaches treatment, will be crucial managing COVID-19 . After first year period which several treatments were employed early intervention strategies, including use antiretrovirals monoclonal antibodies, have emerged as promising mitigate severity fragile individuals prevent disease progression, hospitalization death even recent time less aggressive SARS-CoV-2 variants. Guidelines, high-quality data for combination exploiting antivirals neutralizing antibodies do exist outpatient setting, especially severe individuals. Nevertheless, studies attempted investigate efect this approach although these are often observational without control groups, generally no adverse reactions from therapy been reported. potential efficacy therapy, based an antiviral plus a antibody, severely patients is matter literature debate scientific word. To date, information concerning using combined therapies limited. In Literature Review we explain Last variant updates vulnerable Sars-Cov-2.
Язык: Английский
